BioImagene appoints prominent pathologist Dr Robert J Monroe as Chief Medical Officer
Cupertino, CA, Sep 3, 2008
BioImagene, the leader in providing innovative and affordable
digital pathology solutions for cancer diagnosis and research,
strengthened its executive team with the appointment of Robert
J Monroe, M.D., PH, D, as Chief Medical Officer (CMO).
Dr. Monroe will lead the company’s efforts to develop
and commercialize image analysis applications to provide
customers with the most comprehensive panels for breast,
prostate, lung, colon pathology as well as cytopathology. He
has over 10 years of pathology and research experience and
his appointment follows the recent funding round where BioImagene
raised $26 M for expansion capital and expanded their board.
Mohan Uttarwar, BioImagene CEO said, “Dr. Monroe’s
appointment is a significant step in expanding our lead in
technology innovation and broadening our suite of image analysis
algorithms. We welcome him on board and eagerly anticipate
his contribution towards expanding our digital pathology
applications developed for pathologists, by combining innovations
in image processing with deep knowledge of pathology. His
guidance will accelerate our ongoing development of proprietary
breakthrough technology for computer assisted diagnosis. ”
Dr. Monroe is board certified by the American Board of Pathology
in cytopathology, anatomic pathology and clinical pathology.
He received his degrees in medicine and genetics from Harvard
Medical School and completed his pathology residency in Stanford
and UCLA followed by a cytopathology fellowship at UCLA.
In addition to his impressive medical credentials, he is
the recipient of many honors including the Modell Prize for
Graduate Research in Immunology awarded by the Harvard Medical
School Program in Immunology. Dr. Monroe has published numerous
articles for peer reviewed journals and has shared his expertise
through various lectures and presentations locally and nationally.
Dr. Monroe explained, “The traditional practice of
pathology is being transformed by innovations in technology,
and BioImagene is where it’s happening. I am
happy to work in tandem with their world class management
team to bring pathology into the digital age.”
About BioImagene
BioImagene is a leading provider of total digital pathology
solutions for applications including clinical diagnostics
and drug discovery. BioImagene products are FDA -cleared
for specific clinical applications, and are intended for
research use for other applications. www.bioimagene.com.
Media contact: Suchi Parth 408 207 4285
|
